Status:
COMPLETED
To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg/5 ml Oral Suspension Fed Conditions
Lead Sponsor:
Sandoz
Conditions:
Healthy
Eligibility:
All Genders
18-56 years
Phase:
PHASE1
Brief Summary
To demonstrate the relative bioequivalence of Cefdinir and Omnicel 250 mg/5 ml fed conditions.
Eligibility Criteria
Inclusion
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00883883
Start Date
April 1 2005
End Date
May 1 2005
Last Update
March 29 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.